Premium
Production of β 2 ‐microglobulin by chronic lymphocytic leukaemia cells in vitro
Author(s) -
Simonsson B.,
Danersund A.,
Tötterman T. H.,
Nilsson K.,
Wibell L.
Publication year - 1986
Publication title -
scandinavian journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0036-553X
DOI - 10.1111/j.1600-0609.1986.tb02276.x
Subject(s) - beta 2 microglobulin , in vitro , chronic lymphocytic leukemia , lymphocyte , immunology , medicine , chemistry , microbiology and biotechnology , pathology , biology , leukemia , biochemistry
The in vitro production of β 2 ‐microglobulin (β 2 m) by leukaemic cells was studied in 22 patients with chronic B‐lymphocytic leukaemia (CLL). In addition, the concentration of β 2 m in serum (S‐β 2 m) was determined and expressed as percent of the upper normal limit, after a correction for elevated S‐Creatinine values. Patients with progressive disease usually had CLL cells with a high rate of in vitro synthesis and an increased S‐β 2 m. This was not found in patients with non‐progressive disease. The in vitro synthesis of β 2 m × the lymphocyte count correlated with S‐β 2 m in the total material (r = 0.65). The increased S‐β 2 m frequently observed in CLL may therefore originate from the tumour cells. Hence, S‐β 2 m is promising as a clinically useful tumour cell‐associated marker in CLL.